| Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients SR Plotkin, VL Merker, C Halpin, D Jennings, MJ McKenna, GJ Harris, ... Otology & Neurotology 33 (6), 1046-1052, 2012 | 246 | 2012 |
| Clinical features of schwannomatosis: a retrospective analysis of 87 patients VL Merker, S Esparza, MJ Smith, A Stemmer-Rachamimov, SR Plotkin The oncologist 17 (10), 1317-1322, 2012 | 213 | 2012 |
| Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis SR Plotkin, MA Bredella, W Cai, A Kassarjian, GJ Harris, S Esparza, ... PloS one 7 (4), e35711, 2012 | 168 | 2012 |
| Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2–associated vestibular schwannomas JO Blakeley, X Ye, DG Duda, CF Halpin, AL Bergner, A Muzikansky, ... Journal of Clinical Oncology 34 (14), 1669, 2016 | 114 | 2016 |
| Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients FP Nunes, VL Merker, D Jennings, PA Caruso, E di Tomaso, ... PLoS One 8 (3), e59941, 2013 | 110 | 2013 |
| Understanding relationships between autism, intelligence, and epilepsy: a cross‐disorder approach AM Van Eeghen, MB Pulsifer, VL Merker, AM Neumeyer, EE Van Eeghen, ... Developmental Medicine & Child Neurology 55 (2), 146-153, 2013 | 108 | 2013 |
| Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature AM Vranceanu, VL Merker, E Park, SR Plotkin Journal of neuro-oncology 114, 257-262, 2013 | 104 | 2013 |
| Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation SR Plotkin, L Messiaen, E Legius, P Pancza, RA Avery, JO Blakeley, ... Genetics in Medicine 24 (9), 1967-1977, 2022 | 90 | 2022 |
| Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients KM Slusarz, VL Merker, A Muzikansky, SA Francis, SR Plotkin Cancer chemotherapy and pharmacology 73, 1197-1204, 2014 | 85 | 2014 |
| Mind–body therapy via videoconferencing in patients with neurofibromatosis: An RCT AM Vranceanu, E Riklin, VL Merker, EA Macklin, ER Park, SR Plotkin Neurology 87 (8), 806-814, 2016 | 81 | 2016 |
| Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients SR Plotkin, VL Merker, A Muzikansky, FG Barker, W Slattery III Otology & Neurotology 35 (1), e50-e56, 2014 | 72 | 2014 |
| Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature AM Vranceanu, VL Merker, ER Park, SR Plotkin Journal of neuro-oncology 122, 219-228, 2015 | 64 | 2015 |
| The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study AM Vranceanu, VL Merker, SR Plotkin, ER Park Journal of Neuro-oncology 120, 103-109, 2014 | 64 | 2014 |
| Relationship between whole‐body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis VL Merker, MA Bredella, W Cai, A Kassarjian, GJ Harris, A Muzikansky, ... American Journal of Medical Genetics Part A 164 (6), 1431-1437, 2014 | 59 | 2014 |
| Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials PL Wolters, S Martin, VL Merker, JH Tonsgard, SE Solomon, A Baldwin, ... Neurology 87 (7_Supplement_1), S4-S12, 2016 | 51 | 2016 |
| Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2 S Farschtschi, VL Merker, D Wolf, M Schuhmann, J Blakeley, SR Plotkin, ... Acta Neurologica Scandinavica 133 (6), 475-480, 2016 | 51 | 2016 |
| Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials PL Wolters, S Martin, VL Merker, KL Gardner, CM Hingtgen, JH Tonsgard, ... Neurology 81 (21_supplement_1), S6-S14, 2013 | 49 | 2013 |
| Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis JL Jaremko, PJ MacMahon, M Torriani, VL Merker, VF Mautner, ... Skeletal Radiology, 1-7, 2011 | 42 | 2011 |
| “Because the country, it seems though, has turned their back on me”: experiences of institutional betrayal among veterans living with Gulf War illness K Bloeser, KK McCarron, VL Merker, J Hyde, RE Bolton, N Anastasides, ... Social Science & Medicine 284, 114211, 2021 | 28 | 2021 |
| Pain correlates with germline mutation in schwannomatosis JT Jordan, MJ Smith, JA Walker, S Erdin, ME Talkowski, VL Merker, ... Medicine 97 (5), e9717, 2018 | 28 | 2018 |
Scott R. PlotkinProfessor of Neurology, Harvard Medical School在 post.harvard.edu 的电子邮件经过验证
